Blood clots (thromboembolism) in the lungs, legs and brain (ischaemic stroke) contribute to disability and death of patients with heart failure. Although aspirin is of proven benefit in patients following myocardial infarction, there is inadequate evidence from long term studies to recommend its routine use in patients with heart failure. There is also no evidence to indicate superior effects from oral anticoagulation, when compared to aspirin, in patients with heart failure, although there may be more hospital admissions in those taking aspirin compared to warfarin. There is no presently available prospective evidence from long term studies, to recommend routine use of aspirin to prevent thromboembolism in patients with heart failure who are in sinus rhythm.
There is insufficient evidence to determine effect of aspirin versus anticoagulation or placebo for thromboembolism in patients with chronic heart failure in sinus rhythm.
Published Online:
March 16, 2011
Health topics:
More like this
- Warfarin is the most efficacious agent for prevention of stroke in patients with atrial fibrillation
- Ticlopidine plus aspirin is better than oral anticoagulants alone for reducing the risk of revascularization, non-fatal myocardial infarction and bleeding following stenting of coronary arteries
- Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease
- There is not enough evidence yet to determine if anticoagulants safely prevent blood clots in patients with chronic heart failure in normal heart rhythm.
- Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial treatment of non-ST segment elevation acute coronary syndromes
